大B细胞淋巴瘤患者接受阿基仑赛治疗后神经毒性的临床与影像学相关性
该队列分析纳入100例接受标准治疗阿基仑赛的复发或难治性大B细胞淋巴瘤患者,68%发生任何级别ICANS,41%发生≥3级ICANS;≥3级ICANS与输注后30天内高铁蛋白峰值、高C反应蛋白峰值及低单核细胞峰值相关,并与更短的无进展生存和总生存相关。
要点
- 100例接受阿基仑赛治疗的患者中,68例(68%)发生任何级别ICANS,41例(41%)发生≥3级ICANS。
- ICANS中位起病时间为5天,中位持续时间为6天。
- ≥3级ICANS与输注后30天内高铁蛋白峰值(P = .03)、高C反应蛋白峰值(P = .001)及低单核细胞峰值(P = .001)相关。
核心结论
- 研究结果提示,ICANS患者中影像学和脑电图异常常见,高级别ICANS与LBCl患者CAR T细胞治疗后更差结局相关。
研究设计与样本
- 对100例连续接受标准治疗阿基仑赛的复发或难治性大B细胞淋巴瘤患者进行队列分析,ICANS按客观分级系统分级,神经影像和脑电图由专家神经放射学家和神经学家审阅。
主要发现
- 100例患者中68例(68%)发生任何级别ICANS,41例(41%)发生≥3级ICANS;ICANS中位起病时间为5天,中位持续时间为6天。
- ≥3级ICANS与输注后30天内高铁蛋白峰值(P = .03)、高C反应蛋白峰值(P = .001)及低单核细胞峰值(P = .001)相关。
- 38例ICANS患者接受磁共振成像,显示4种影像模式:脑炎特征(n = 7)、卒中(n = 3)、软脑膜疾病(n = 2)和可逆性后部脑病综合征(n = 2)。
- 脑电图异常包括弥漫性慢波(n = 49)、癫痫样放电(n = 6)和非惊厥性癫痫持续状态(n = 8)。
- 尽管可逆,≥3级ICANS与显著更短的无进展生存(P = .02)和总生存(P = .001)相关,疾病进展为最常见死因。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Neurotoxicity or immune effector cell-associated neurotoxicity syndrome (ICANS) is the second most common acute toxicity after chimeric antigen receptor (CAR) T-cell therapy. However, there are limited data on the clinical and radiologic correlates of ICANS. We conducted a cohort analysis of 100 consecutive patients with relapsed or refractory large B-cell lymphoma (LBCL) treated with standard of care axicabtagene ciloleucel (axi-cel). ICANS was graded according to an objective grading system. Neuroimaging studies and electroencephalograms (EEGs) were reviewed by an expert neuroradiologist and neurologist. Of 100 patients included in the study, 68 (68%) developed ICANS of any grade and 41 (41%) had grade ≥3. Median time to ICANS onset was 5 days, and median duration was 6 days. ICANS grade ≥3 was associated with high peak ferritin (P = .03) and C-reactive protein (P = .001) levels and a low peak monocyte count (P = .001) within the 30 days after axi-cel infusion. Magnetic resonance imaging was performed in 38 patients with ICANS and revealed 4 imaging patterns with features of encephalitis (n = 7), stroke (n = 3), leptomeningeal disease (n = 2), and posterior reversible encephalopathy syndrome (n = 2). Abnormalities noted on EEG included diffuse slowing (n = 49), epileptiform discharges (n = 6), and nonconvulsive status epilepticus (n = 8). Although reversible, grade ≥3 ICANS was associated with significantly shorter progression-free (P = .02) and overall survival (progression being the most common cause of death; P = .001). Our results suggest that imaging and EEG abnormalities are common in patients with ICANS, and high-grade ICANS is associated with worse outcome after CAR T-cell therapy in LBCL patients.
引用
- Strati P, Nastoupil LJ, Westin J, et al. Clinical and radiologic correlates of neurotoxicity after axicabtagene ciloleucel in large B-cell lymphoma. Blood Adv. 2020. PMID: 32822484. doi:10.1182/bloodadvances.2020002228
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。